Moving combination ICI to earlier disease stages (neoadjuvant therapies), selecting patients with a higher IFN-γ signature for dual ICI, or offering novel (triple) therapies might improve the ICI efficacy for patients with this rare cancer. This evidence concerns the gene IFNG and cancer.